Lidocaine/dibucaine CRPs
This article was originally published in The Tan Sheet
Executive Summary
Consumer Product Safety Commission will provide options to its commissioners on how to proceed with proposal to require child- resistant packaging for OTC lidocaine and dibucaine products in the near future, CPSC tells Nonprescription Drug Manufacturers Association during meeting May 25 at CPSC headquarters. One option, CPSC said, is that the reg is "technically feasible, practical and appropriate" and should be finalized. NDMA maintained that acceptable CRP technology for lidocaine/dibucaine products is not available and the cost necessary to develop it is too high in light of the small size of the market for those products. NDMA reiterated that adverse experiences from lidocaine/dibucaine do not warrant CRPs ("The Tan Sheet" Sept. 6, 1993, In Brief). CPSC said that it will take NDMA's complaints into account